Stem Cell Transplantation Clinical Trial
Official title:
Pilot Study of Sirolimus, Tacrolimus and Short Course Methotrexate for Prevention of Acute Graft Versus Host Disease in Recipients of Mismatched Unrelated Donor Allogeneic Stem Cell Transplantation
Verified date | November 2016 |
Source | Yale University |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The primary objective of this trial is to study the safety and efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate as prophylaxis against acute graft versus host disease (GVHD) in recipients of mismatched unrelated donor stem cell grafts. Methotrexate is administered in a low dose format of 5mg/m2 on days +1,3 and 6 only.
Status | Completed |
Enrollment | 26 |
Est. completion date | October 2014 |
Est. primary completion date | October 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 16 Years and older |
Eligibility |
Inclusion Criteria: - Patients must have an identified 8/10 or 9/10 matched unrelated donor identified following a formal search with confirmatory typing through the national marrow donor program as the best available donor. No matched sibling or fully matched unrelated donor has been identified. HLA typing of donor and recipient will be performed by high resolution molecular typing at HLA A, B, C and DRB1/DQ loci. Patients whose best available donor is matched at 8/10 loci must have at least one of the mismatches at the DQ locus. (no more than one mismatch at HLA A,B,C,DR allowed). - Candidates for this trial will meet the following criteria: 1. Adequate organ function for conditioning type: For patients receiving ablative conditioning - Left Ventricular ejection fraction >45% - DLCO >50% - Creatinine <1.5 - Hepatic enzymes <3x upper limit of normal. - KPS >70% For patients receiving non-ablative conditioning: - KPS >70% 2. Patients with the following diseases will be considered eligible: - AML in first remission with high risk features (poor risk cytogenetic abnormalities9, persistent elevated blast count on day +15 or recovery marrow after induction therapy). - AML beyond first remission - ALL in first remission with high risk features (ph+, t4:11) - ALL beyond first remission - High risk Myelodysplasia (RAEB-II, RAEB-I with poor-risk cytogenetics) - Recurrent Aggressive Non-Hodgkins or Hodgkins lymphoma (indolent histologies excluded) who have failed autologous transplant or have had inadequate response to salvage therapy. - CML with transformation - CLL with transformation or Fludarabine failure. - Severe aplastic anemia with recurrence or failure after immunosuppressive therapy. Exclusion Criteria: - Prior allogeneic transplantation - Active CNS leukemia. - Female patients who are pregnant or breast feeding - Karnofsky performance status <70%. - Active viral, bacterial or fungal infection. - Patients seropositive for HIV -1,2; HTLV -1,2 (due to the additional immunodeficiency induced by transplantation and immunosuppressive therapy) Requirement for antifungal prophylaxis with Voriconazole for the first 30 days is prohibited. - Patients not providing informed consent. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Yale University School of Medicine | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Yale University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety/Efficacy of a novel regimen of sirolimus, tacrolimus and methotrexate | Upon completion of study | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03918343 -
Lipopolysaccharide Metabolism and Identification of Potential Biomarkers Predictive of Graft-versus-host Disease After Allogeneic Stem Cell Transplantation
|
N/A | |
Not yet recruiting |
NCT05438823 -
Technology Supported Education Program Based on Human Care Theory
|
N/A | |
Not yet recruiting |
NCT02193399 -
Physiotherapy in Hematopoietic Stem Cell Transplantation
|
N/A | |
Withdrawn |
NCT00972101 -
Infusion of Expanded Cord Blood T Cells
|
Phase 1 | |
Completed |
NCT05421299 -
A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
|
||
Completed |
NCT04976933 -
Post-HSCT Medication Adherence mHealth App
|
||
Completed |
NCT04798495 -
Feasibility of a Rehabilitation Programme Targeted Patients Treated With Non-myeloablative Stem Cell Transplantation
|
N/A | |
Active, not recruiting |
NCT04511130 -
Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant
|
Phase 2 | |
Recruiting |
NCT05968963 -
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT02940093 -
Pipeline Integrating Gut Metagenome Data, Host Immunogenetic Characteristics and Clinical Gut Inflammatory Biomarkers
|
N/A | |
Not yet recruiting |
NCT06077734 -
Muscle Stem Cell Quality in Atrophy
|
||
Terminated |
NCT00587990 -
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
|
Phase 1/Phase 2 | |
Terminated |
NCT00597441 -
Phase I Study of Umbilical Cord Blood Transplantation Followed by Third Party Thymus Transplantation
|
Phase 1 | |
Active, not recruiting |
NCT03684083 -
Inflammatory Response to Paramyxovirus Infection in an Ex-vivo Model of Bronchial Epithelial Cells in Allogeneic HSCT Recipients
|
||
Recruiting |
NCT00884338 -
Cognitive Function After Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00284713 -
Progenitor Cell Therapy in Dilative Cardiomyopathy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00062543 -
Hepatic Artery Infusion of CD34+ Cells
|
Phase 1 | |
Completed |
NCT00781170 -
Dose-Reduced Allogeneic Stem Cell Transplantation After Autologous High-Dose Chemotherapy in Patients With Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT03364257 -
iDTECT Blood Performance for the Identification of Viral or Bacterial Pathogens in Febrile Neutropenic Patients
|
||
Enrolling by invitation |
NCT06134297 -
Adherence, Viability, Clinical Evolution and Therapeutic Efficacy in Patients Undergoing Bone Marrow Transplantation
|
N/A |